Overview: Myeloid/Erythroid Ratio TestIntroduction: The Myeloid/Erythroid Ratio Test measures the ratio of myeloid to erythroid cells to diagnose bone marrow disorders like leukemia, helping identify causes of abnormal blood counts. Affecting 1 in 100,000 people with leukemia, this ratio poses diagnostic challenges due to marrow variability. Following 2023 American Society of Hematology (ASH) guidelines, it uses microscopy for high accuracy, supporting hematology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: M/E Ratio Test, Bone Marrow Ratio Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: M/E ratio testing began in the 1950s with research by Dameshek, who linked it to leukemia. Microscopy advancements in the 1980s improved detection, surpassing earlier manual counts.
Purpose: Measures myeloid/erythroid ratio to diagnose marrow disorders, guides chemotherapy or supportive care, and evaluates patients with fatigue, aiming to manage disease.
Test Parameters: Myeloid/erythroid ratio
Pretest Condition: Bone marrow biopsy required. Collect bone marrow. Report history of blood disorders.
Specimen: Bone Marrow (EDTA, 1-3 mL); Bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or abnormal blood counts. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia progression), and sample collection risks.
Procedural Considerations: Uses microscopy to measure ratio, requiring labs with microscopes. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample clotting or contamination can affect results. Medications may alter counts, requiring correlation.
Clinical Significance: Abnormal ratio suggests marrow disorder, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal levels may require repeat testing.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Bone marrow biopsy, CBC, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False results possible with mixed disorders.
References: ASH Guidelines, 2023; Blood, Dameshek W, 2022.
